PT771217E - Formas faramceuticas solidas clatratos da hormona sexual esteroide etinilestradiol - Google Patents

Formas faramceuticas solidas clatratos da hormona sexual esteroide etinilestradiol

Info

Publication number
PT771217E
PT771217E PT95943492T PT95943492T PT771217E PT 771217 E PT771217 E PT 771217E PT 95943492 T PT95943492 T PT 95943492T PT 95943492 T PT95943492 T PT 95943492T PT 771217 E PT771217 E PT 771217E
Authority
PT
Portugal
Prior art keywords
steroid
faramceutical
etinylstradiol
clatrates
solid
Prior art date
Application number
PT95943492T
Other languages
English (en)
Inventor
Thomas Backensfeld
Johannes Tack
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6524338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT771217(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of PT771217E publication Critical patent/PT771217E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
PT95943492T 1994-07-20 1995-07-10 Formas faramceuticas solidas clatratos da hormona sexual esteroide etinilestradiol PT771217E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4426709A DE4426709A1 (de) 1994-07-20 1994-07-20 Steroidale Sexualhormone enthaltende feste Arzneiformen

Publications (1)

Publication Number Publication Date
PT771217E true PT771217E (pt) 2004-08-31

Family

ID=6524338

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95943492T PT771217E (pt) 1994-07-20 1995-07-10 Formas faramceuticas solidas clatratos da hormona sexual esteroide etinilestradiol

Country Status (11)

Country Link
US (1) US5798338A (pt)
EP (1) EP0771217B1 (pt)
JP (1) JPH10502912A (pt)
AT (1) ATE263578T1 (pt)
CA (1) CA2194979C (pt)
DE (4) DE4426709A1 (pt)
DK (1) DK0771217T3 (pt)
ES (1) ES2218561T3 (pt)
FR (1) FR07C0001I2 (pt)
PT (1) PT771217E (pt)
WO (1) WO1996002277A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19652196A1 (de) * 1996-12-16 1998-06-18 Jenapharm Gmbh Homogene steroidhaltige Präformulierungen zur Herstellung niedrigdosierter fester und halbfester pharmazeutischer Zubereitungen
DE19848303A1 (de) * 1998-10-14 2000-04-20 Schering Ag Kombination aus Gestagenen und Zuckern
EP1353699B1 (en) * 2000-12-20 2012-02-01 Bayer Pharma Aktiengesellschaft Beta-cyclodextrin-drospirenone inclusion complexes
EP1216712A1 (en) 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
US20070287684A1 (en) * 2006-05-22 2007-12-13 Irshad Chaudry Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
KR20100117603A (ko) * 2008-02-13 2010-11-03 바이엘 쉐링 파마 악티엔게젤샤프트 안정화 효과를 갖는 약물 전달 시스템
WO2009101021A2 (en) * 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
WO2009132208A1 (en) * 2008-04-24 2009-10-29 Evestra, Inc. Oral contraceptive dosage forms comprising a progestogen dispersed in an enteric polymer and further comprising an estrogen
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
CA2796139A1 (en) 2010-04-15 2011-10-20 Bayer Intellectual Property Gmbh Low-dosed solid oral dosage forms for hrt
CA2795801C (en) 2010-04-15 2018-05-29 Bayer Intellectual Property Gmbh Very low-dosed solid oral dosage forms for hrt
CN101869113B (zh) * 2010-06-17 2013-09-04 中国农业科学院植物保护研究所 一种鼠类不育剂的环糊精包合物及其制备方法
AU2011303475B2 (en) 2010-09-16 2016-07-14 Shimoda Biotech (Pty) Ltd Fulvestrant compositions and methods of use
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US9359451B2 (en) 2012-05-15 2016-06-07 The Uab Research Foundation Methods and compositions for treating trauma-hemorrhage using estrogen and derivatives thereof
PT3681475T (pt) 2017-10-16 2021-03-08 Faes Farma Sa Composições aquosas compreendendo bilastina e mometasona
EP3666260A1 (en) * 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
CN114225050B (zh) * 2022-01-29 2022-12-13 国家卫生健康委科学技术研究所 炔雌醇环糊精复合物的制备及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106698A (en) * 1980-12-22 1982-07-02 Kyowa Hakko Kogyo Co Ltd Easily absorbable map composition and preparation containing the same
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPH0764884B2 (ja) * 1986-11-27 1995-07-12 株式会社トクヤマ シクロデキストリン組成物
US4877774A (en) * 1987-09-09 1989-10-31 The United States Of America As Represented By The Department Of Health And Human Services Administration of steroid hormones

Also Published As

Publication number Publication date
ES2218561T3 (es) 2004-11-16
FR07C0001I1 (pt) 2007-03-09
US5798338A (en) 1998-08-25
EP0771217A1 (de) 1997-05-07
CA2194979A1 (en) 1996-02-01
DE4426709A1 (de) 1996-01-25
FR07C0001I2 (pt) 2009-01-02
WO1996002277A1 (de) 1996-02-01
JPH10502912A (ja) 1998-03-17
ATE263578T1 (de) 2004-04-15
DK0771217T3 (da) 2004-08-02
DE122007000011I1 (de) 2007-05-10
EP0771217B1 (de) 2004-04-07
DE59510887D1 (de) 2004-05-13
DE122007000013I1 (pt) 2007-04-26
CA2194979C (en) 2009-01-06

Similar Documents

Publication Publication Date Title
PT771217E (pt) Formas faramceuticas solidas clatratos da hormona sexual esteroide etinilestradiol
ES2123547T3 (es) Formulaciones, metodos y dispositivos contraceptivos transdermicos.
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
BR0012908A (pt) Método para preparar uma composição oral estável antibacteriana contendo uma lupulona hidrogenada, e, composição oral estável antibacteriana
BR9810495A (pt) Composição farmacêutica
CL2010000018A1 (es) Fragmentos de peptido amiloide beta(ab) ab 1-7 y ab 3-7 ligados a un peptido portador, composicion farmaceutica que lo comprende y su uso para tratar la enfermedad de alzheimer
MXPA01007411A (es) Composiciones y metodos para suministro mucoso.
EA200201000A1 (ru) Гормон-заместительная терапия
SE9601421D0 (sv) New composition
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
CL2011000017A1 (es) Uso de una composicion farmaceutica que comprende i) 0,5 a 3 mg de un estrogeno seleccionado de estradiol libre, estradiol esterificado y estrogenos conjugados de equinos, ii) 1,5 a 3,75 de acetato de nomegestrol, y iii) excipientes farmaceuticos adecuados, para tratar deficiencias estrogenicas en mujeres postmenopausicas (divisional de solicitud 1997-02114).
PT1137409E (pt) Composicoes e metodos para melhoramento da disfuncao sexual feminina humana
CO4970835A1 (es) Inhibicion de la oxidacion de lipoproteinas
BR9612207A (pt) Processo e kit para contracepções em mamíferos fêmeas consistindo de uma combinação de gestageno e estrogênio
NZ505073A (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant, useful for treating allergic, inflammatory and intestinal diseases
AP1424A (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens.
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
AU4830097A (en) Use of an extract of Cimicifuga
IT1319275B1 (it) Uso del baclofen nel trattamento dell'astinenza da etanolo.
AU3111195A (en) Alginate fibres, manufacture and use
CA2432534A1 (en) Gel composition and trans-scrotal application of a composition for the treatment of hypogonadism
PL320198A1 (en) Children-safe active substance plaster package
GR900100489A (el) Συνθέσεις χρήσιμοι ως αντισυλληπτικά για άνδρες.
HUP9902286A2 (hu) Javított gyógyászati készítmény szteroidvegyületek adagolására
CA2421302A1 (en) 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds